Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TRIL Trillium Therapeutics (TRIL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Trillium Therapeutics Stock (NASDAQ:TRIL) 30 days 90 days 365 days Advanced Chart Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Trillium Therapeutics alerts:Sign Up Key Stats Today's Range$18.44▼$18.4450-Day Range$17.50▼$18.4452-Week Range$5.80▼$20.96Volume8 shsAverage Volume1.87 million shsMarket Capitalization$1.94 billionP/E Ratio29.74Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Read More… New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Receive TRIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRIL Stock News HeadlinesWhen You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 21, 2024 | Priority Gold (Ad)Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodJuly 31, 2023 | uk.finance.yahoo.comWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'April 26, 2023 | msn.comLeukemia Therapeutics Global Market Report 2023April 4, 2023 | uk.finance.yahoo.comRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckMarch 28, 2023 | finance.yahoo.comSee More Headlines TRIL Stock Analysis - Frequently Asked Questions How were Trillium Therapeutics' earnings last quarter? Trillium Therapeutics Inc. (NASDAQ:TRIL) issued its quarterly earnings data on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include NVIDIA (NVDA), CannaPharmaRX (CPMD), FuelCell Energy (FCEL), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/18/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TRIL CUSIPN/A CIK1616212 Webwww.trilliumtherapeutics.com Phone(416) 595-0627FaxN/AEmployees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.62 Trailing P/E Ratio29.74 Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,350,000.00 Net MarginsN/A Pretax Margin-113,720.92% Return on Equity-23.31% Return on Assets-18.66% Debt Debt-to-Equity RatioN/A Current Ratio19.82 Quick Ratio19.82 Sales & Book Value Annual Sales$150,000.00 Price / Sales12,907.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book7.20Miscellaneous Outstanding Shares104,995,000Free Float95,440,000Market Cap$1.94 billion OptionableOptionable Beta2.08 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:TRIL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trillium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
